A Bipartisan Coalition of 39 State Attorneys General Urge Congressional Action on Pharmacy Benefit Manager Reform

The National Association of Attorneys General (NAAG) sent a letter to Congressional leaders on behalf of 39 attorneys general who urge congressional leaders to engage in meaningful debate and reform of the current practices of pharmacy benefit managers (PBMs) and to take decisive action to reform the way PBMs conduct business and bring more transparency…

Read More →

State Attorneys General Urge Bridge Funding for the Federal Crime Victims Fund (VOCA)

A bi-partisan coalition of 42 state attorneys general urge the U.S. Senate and House of Representatives to authorize much-needed 2024 bridge funding for the federal Crime Victims Fund (the “VOCA Fund.”) The VOCA Fund supports the provision of essential direct services for crime victims and survivors across the country. According to the U.S. Department of…

Read More →

45 State Attorneys General Join in their Ongoing Efforts to Protect Consumers from Robocalls

A bi-partisan coalition of 45 state attorneys general sent a letter to the Federal Communications Commission (FCC) seeking to safeguard consumers from scam phone calls made by Voice-Over-Internet-Protocol (VoIP) service providers. The attorneys general submitted comments to the FCC on its proposal “to safeguard and secure the open Internet” (NPRM) asking it to clarify that…

Read More →

FTC and Plaintiff States v. Amazon.com, Inc., No. 2:23-cv-01495 (W.D. Wash. Sept. 26, 2023)

The FTC and plaintiff states alleged that Amazon, an online retail and technology company, is a monopolist that uses a set of interlocking anticompetitive and unfair strategies to illegally maintain its monopoly power. The lawsuit alleges that Amazon’s actions allow it to stop rivals and sellers from lowering prices, degrade quality for shoppers, overcharge sellers,…

Read More →

54 Attorneys General Call on Congress to Study AI and Its Harmful Effects on Children

A bipartisan coalition of 54 state and territory attorneys general urge Congress to study how artificial intelligence (AI) can and is being used to exploit children through child sexual abuse material (CSAM). The attorneys general also asked Congress to propose legislation that would protect children from those abuses. The National Association of Attorneys General (NAAG)…

Read More →

Bipartisan Coalition of Attorneys General Express Support for the G.U.A.R.D. VA Act

A bipartisan coalition of 44 attorneys general express support for the passage of legislative proposals included in Governing Unaccredited Representatives Defrauding (G.U.A.R.D.) Veterans Affairs (VA) Benefits Act. In a letter to congressional leaders, the attorneys general explain that the passing of the bipartisan legislation would hold unaccredited and unregulated actors accountable for targeting and preying…

Read More →

Attorneys General Call on Congress to Pass the Combating Illicit Xylazine Act

A bipartisan coalition of 39 state and territory attorneys general called on leaders of Congress to pass the Combating Illicit Xylazine Act (H.R.1839/S.993). Xylazine is only approved by the U.S. Food and Drug Administration (FDA) as a veterinary medicine and in humans, it is known to depress breathing and heart rate, lower blood pressure, and…

Read More →

Attorneys General Urge Congress to Appropriate Funding for Legal Services Corporation

A bipartisan coalition of 37 state and territory attorneys general urge leaders of the U.S. House and Senate Appropriations Committees to allocate robust funding for the nonprofit Legal Services Corporation (LSC) in the FY2024 budget. LSC supports equal access to justice by awarding grants to nonprofit organizations that provide civil legal services to those in…

Read More →

Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)

44 plaintiff states filed suit against Teva Pharmaceuticals and 19 of the nation’s largest generic drug manufacturers alleging a broad conspiracy to artificially inflate and manipulate prices, reduce competition and unreasonably restrain trade for more than 100 different generic drugs. The lawsuit was originally Connecticut, was transferred to the MDL court in Pennsylvania.  The lawsuit…

Read More →

Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)

Plaintiff states filed a third lawsuit stemming from the ongoing antitrust investigation into a widespread conspiracy by generic drug manufacturers to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for generic drugs sold across the United States. The complaint focuses on 80 topical generic drugs  and names 26 corporate Defendants and 10…

Read More →